Global Medicare · Patient FAQs
Clear answers for the questions that come first.
Find approved general information about Global Medicare, the Ovarian and Endometrial Programs, Standard-PRP and IAS, research, costs, privacy, safety and visiting IVF Baden-Baden.
This information is general and does not replace specialist medical advice, diagnosis, medication instructions or individual interpretation of clinical results.
Find an answer
Search by question or browse by topic.
If your question concerns your individual diagnosis, medication, symptoms, prognosis or treatment decision, general FAQ information cannot replace the medical team.
What does Global Medicare help with?
Global Medicare provides approved general information, initial orientation and coordination to help patients navigate an appropriate specialist fertility pathway.
Medical diagnosis, interpretation of individual results and treatment decisions remain with authorised healthcare professionals.
Do I need a diagnosis before contacting Global Medicare?
No. You can begin by explaining the general reason
you are seeking another fertility evaluation,
specialist perspective or international pathway.
Can Global Medicare interpret my medical results?
No. Individual laboratory results, ultrasound findings,
previous IVF outcomes and other clinical information
must be interpreted by the medical team within the
complete clinical context.
Is participation in the research studies voluntary?
Yes. Research participation is voluntary.
A participant may withdraw without having to justify
the decision and without affecting normal medical care.
What is ExoRegenOvo?
ExoRegenOvo is the commercial name used for
the ovarian research program associated with
Study 02-REGEN-AR at IVF Baden-Baden.
What is the main objective of 02-REGEN-AR?
The primary objective is to compare the
total number of transferable embryos
obtained during a treatment sequence of up to
three stimulation cycles between patients receiving
Standard-PRP and IAS within routine clinical care.
What age group is included in the ovarian study?
The general study population is women aged
30–47 years at screening.
Age alone does not determine eligibility.
What ovarian profiles are represented in the study?
General profiles include reduced ovarian reserve
within POSEIDON groups I–IV, advanced maternal age
and PCOS according to Rotterdam criteria.
These profiles do not confirm individual eligibility.
Can you tell me whether my AMH or AFC means I qualify?
No. Global Medicare can explain what AMH and AFC refer to,
but individual values must be interpreted by the medical team
and cannot by themselves confirm study eligibility.
How many stimulation cycles may be included?
Up to three stimulation cycles may form part
of the treatment sequence.
The third cycle is optional and depends on the
clinical course and medical judgement.
Is Standard-PRP or IAS administered during every ovarian cycle?
No.
Standard-PRP or IAS may be applied intraovarian during
the first and second retrievals.
There is no new PRP/IAS application during the
optional third retrieval.
How long can the ovarian pathway take?
As general orientation, approximately 8–9 weeks
to embryo transfer with two cycles and around
12–14 weeks with three cycles.
Individual timing is determined by the clinical team.
Can the Ovarian Program guarantee that I will avoid egg donation?
No.
Specialist evaluation may help review whether additional
clinical possibilities should be considered before
an important decision, but no avoidance of egg donation,
pregnancy or other result can be guaranteed.
What is RegenEndo?
RegenEndo is the endometrial research program
associated with Study 03-REGEN-AR
at IVF Baden-Baden.
What is the main objective of RegenEndo?
The primary objective is to compare
endometrial development, particularly endometrial thickness,
after Standard-PRP or IAS.
What age group is included in RegenEndo?
The general endometrial study population
is women aged 20–50 years.
Age alone does not determine eligibility.
What endometrial situations are represented in the study?
General profiles include Asherman syndrome after adhesiolysis,
thin or atrophic endometrium, previously treated chronic
endometritis, adenomyosis, repeated implantation failure
and recurrent pregnancy loss without another identified cause.
How is the first endometrial application performed?
The first application is subendometrial and is performed
by hysteroscopy under sedation within the clinical pathway.
Individual procedural instructions are provided by
the clinical team.
Can additional endometrial applications be performed?
If the clinical response is considered insufficient,
up to three additional intracavitary instillations may
be performed approximately every 48 hours according
to the individual clinical plan.
What does the 6.5 mm endometrial reference mean?
The protocol uses 6.5 mm as a reference,
not as an automatic decision rule.
Clinical management may continue toward embryo transfer
even when that value is not reached if the medical team
considers it appropriate.
Can Global Medicare interpret my endometrial thickness?
No.
A numerical ultrasound result must be interpreted
together with morphology, vascularisation, reproductive
history and the rest of the clinical context by the medical team.
What endometrial parameters may be observed?
The research framework can document endometrial thickness,
volume, morphology and vascularisation parameters,
including VI, FI and VFI.
These are study measurements, not an online prediction
of implantation or pregnancy.
Are Standard-PRP and IAS made from donor material?
No.
Both are autologous preparations based on material
obtained from the patient herself.
What is IAS?
IAS is an autologous preparation that includes
additional processing steps to recover and recombine
naturally occurring components from fractions of
the same blood sample.
Is IAS a purified exosome therapy?
No.
IAS should not be described as purified exosome therapy
or as containing a guaranteed dose of exosomes.
Is IAS better than Standard-PRP?
Global Medicare does not present IAS as clinically
superior to Standard-PRP.
The current observational studies are designed
to document and compare outcomes associated with
the two preparation approaches.
What are 02-REGEN-AR and 03-REGEN-AR?
They are two prospective, observational,
single-centre and non-randomised studies
conducted at IVF Baden-Baden.
02-REGEN-AR / ExoRegenOvo focuses on ovarian and IVF / ICSI outcomes.
03-REGEN-AR / RegenEndo focuses on endometrial development and implantation-related parameters.
Does the study decide whether I receive Standard-PRP or IAS?
No.
The choice is made by the clinical team according
to the individual situation, availability and informed
patient preference before and independently of
research participation.
Can Global Medicare confirm whether I am eligible for a study?
No.
Global Medicare can provide approved general information
and initial orientation.
Final eligibility belongs to the authorised
medical and research teams after review of the full protocol criteria.
Can I enrol directly in a study through the website?
The website does not confirm direct study inclusion.
The pathway begins with initial orientation and
clinical evaluation.
Any possible research participation is assessed later
and independently by the authorised research team.
Does completing a Global Medicare form mean I consent to research?
No.
A website form, chatbot conversation or initial orientation
does not replace formal informed consent for research.
Research consent is handled through the authorised
study process.
Does research participation guarantee a health or pregnancy benefit?
No.
Participation in observational research does not guarantee
improved ovarian or endometrial parameters, implantation,
pregnancy, live birth or another individual clinical benefit.
Is the fertility treatment free because I participate in research?
No.
Participation in the research does not add
research-specific costs, but routine clinical care
may involve costs that must be confirmed with administration.
“No additional research cost” does not mean free fertility treatment.
Are research data anonymous?
The correct term is pseudonymised,
not anonymous.
The correspondence key remains under the control
of IVF Baden-Baden / the Principal Investigator.
Does IHH Regenerics receive my direct identity?
Within the approved research framework,
IHH Regenerics receives pseudonymised data and
research material for authorised scientific purposes
and does not receive direct identifying information.
What research samples may be collected in 02-REGEN-AR?
Research may involve aliquots of blood,
PRP, IAS and cumulus cells where applicable
and authorised.
Oocytes, embryos and follicular fluid should not
be described as research samples in the public pathway.
What research samples may be collected in 03-REGEN-AR?
Research may involve aliquots of blood,
PRP and IAS where applicable and authorised.
An endometrial biopsy or tissue sample should not
be described as a routine research sample unless
separately authorised.
Where are the current studies conducted?
Both current studies are conducted at
IVF Baden-Baden in Germany
under the direction of Prof. Dr. med. Wolfgang Küpker.
Do I need to travel to Baden-Baden?
The current clinical and research pathways require
availability for the relevant visits at IVF Baden-Baden.
The exact number and timing of visits depend on
the individual clinical pathway.
Should I book travel before the clinical schedule is confirmed?
Travel should be organised around the confirmed
clinical pathway and the timing provided by the medical team.
Can Global Medicare tell me what medication or dose to take?
No.
Medication, doses, start dates, stopping medication
and missed-dose instructions depend on the individual
clinical plan.
Follow only the written instructions provided by
your medical team and contact them before changing
medication.
I forgot a medication dose. What should I do?
Contact the clinical team.
Do not change, repeat or compensate for a dose
on your own unless the medical team instructs you to do so.
I have pain, fever, bleeding or feel worse after a procedure. What should I do?
Do not rely on the website or Patient Assistant
to assess current symptoms.
Contact the clinical centre treating you.
If you have severe pain or bleeding,
difficulty breathing, fainting or rapid deterioration,
seek urgent medical care.
No questions match your search.
Try another term or contact Global Medicare.
Still have a question?
Some questions need information. Others need a specialist.
Global Medicare can help with approved general information and orientation. Individual medical decisions remain with the appropriate healthcare professional.
Your next step
General information can answer a question. Specialist assessment addresses your case.
If your question concerns your individual fertility situation, begin with the patient pathway rather than trying to reach a medical conclusion from general information alone.